CHAPTER 4 202 REFERENCES 1. Joseph P, Dokainish H, McCready T, Budaj A, Roy A, Ertl G, et al. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (GCHF) registry. American Heart Journal 2020;227:56–63. doi:10.1016/j.ahj.2020.06.002. 2. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive populationbased characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017;19:1624–1634. doi:10.1002/ejhf.945. 3. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola V-P, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure 2017;19:1574–1585. doi:10.1002/ejhf.813. 4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. doi:10.1093/eurheartj/ehab368. 5. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533. doi:10.1056/NEJM199702203360801. 6. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–885. doi:10.1016/S0140-6736(10)61198-1. 7. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:1883–1893. doi:10.1056/NEJMoa1915928. 8. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of SodiumGlucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol 2020;5:948–951. doi:10.1001/jamacardio.2020.0898. 9. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515–523. doi:10.1161/CIRCULATIONAHA.108.812172. 10. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25–32. doi:10.1093/eurheartj/eht278. 11. Sidney S, Quesenberry CP, Jaffe MG, Sorel M, Go AS, Rana JS. Heterogeneity in national U.S. mortality trends within heart disease subgroups, 2000–2015. BMC Cardiovascular Disorders 2017;17:192. doi:10.1186/s12872-017-0630-2. 12. Weber C, Hung J, Hickling S, Li I, Murray K, Briffa T. Changing age-specific trends in incidence, comorbidities and mortality of hospitalised heart failure in Western Australia between 2001 and 2016. Int J Cardiol 2021;343:56–62. doi:10.1016/j.ijcard.2021.09.015. 13. Lim YMF, Ong SM, Koudstaal S, Hwong WY, Liew HB, Rajadurai J, et al. Trends for Readmission and Mortality After Heart Failure Hospitalisation in Malaysia, 2007 to 2016. Glob Heart 2022;17:20. doi:10.5334/gh.1108. 14. Janwanishstaporn S, Karaketklang K, Krittayaphong R. National trend in heart failure hospitalization and outcome under public health insurance system in Thailand 2008–2013. BMC Cardiovascular Disorders 2022;22:203. doi:10.1186/s12872-022-02629-2. 15. Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol 2018;3:1011–1019. doi:10.1001/jamacardio.2018.2559.
RkJQdWJsaXNoZXIy MjY0ODMw